Current Report Filing (8-k)
December 01 2021 - 5:11PM
Edgar (US Regulatory)
0001552189
false
0001552189
2021-11-30
2021-11-30
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
DC 20549
Form
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): November 30, 2021
PANACEA
LIFE SCIENCES HOLDINGS, INC.
(Exact
name of the registrant as specified in its charter)
Nevada
|
|
001-38190
|
|
27-1085858
|
(State
or other jurisdiction of
|
|
(Commission
|
|
(IRS
Employer
|
of
incorporation)
|
|
File
Number)
|
|
Identification
No.)
|
5910
South University Blvd, C18-193
Greenwood
Village, CO 80121
(Address
of principal executive offices) (Zip code)
Registrant’s
telephone number, including area code: 1-800-985-0515
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under
any of the following provisions (see General Instruction A.2 below):
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
|
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).
|
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
symbol(s)
|
|
Name
of exchange on which registered
|
N/A
|
|
N/A
|
|
N/A
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
1.01 Entry into a Material Definitive Agreement.
On
November 30, 2021, Panacea Life Sciences Holdings, Inc. (the “Company”) closed on the private placement transaction previously
disclosed on the Company’s Current Report on Form 8-K filed on November 24, 2021, and received a wire transfer of $1,000,000.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on behalf of the
undersigned hereunto duly authorized.
|
Panacea
Life Sciences Holdings, Inc.
|
Date:
December 1, 2021
|
|
|
|
By:
|
/s/
Leslie Buttorff
|
|
Name:
|
Leslie
Buttorff
|
|
Title:
|
Chief
Executive Officer
|
Panacea Life Sciences (PK) (USOTC:PLSH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Panacea Life Sciences (PK) (USOTC:PLSH)
Historical Stock Chart
From Jul 2023 to Jul 2024